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Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to 
represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs rep-
resent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects 
of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and 
Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity.
Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single 
daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 
1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus 
and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evalu-
ated according to the Modified Mayo Disease Activity Index.
Results. All patients treated with combination therapy showed better improvement compared to the controls. In 
particular, the beneficial effects of probiotics were evident even after two years of treatment.
Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an 
alternative to corticosteroids in mild-to moderate ulcerative colitis.
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INTRODUCTION
inflammatory bowel disease worldwide incidence and 
prevalence have been increasing in the last few decades. 
Ulcerative colitis (Uc) is one of the two major types of 
iBd, along with crohn disease (cd). Unlike cd, which 
can affect any part of the gastrointestinal tract, Uc char-
acteristically involves the large bowel1,2. 
There is a large debate about the exact aetiology of 
Uc. proposed causes include environmental factors, im-
mune dysfunction, and a likely genetic predisposition. 
The current hypothesis is that genetically susceptible in-
dividuals have abnormalities of humoral and cell-mediated 
immunity and a generalized enhanced reactivity against 
commensal intestinal bacteria3. This dysregulated muco-
sal immune response predisposes to colonic inflamma-
tion3. Whether these abnormalities are the cause or the 
result of the intense systemic inflammatory response in 
Uc is still unresolved. However, it is well documented 
that bacterial microflora is altered in patients with active 
disease4. recent studies reported a great variation in the 
effects of microbiota, focusing, in particular, on the effects 
of a pro-inflammatory enterotype on mucosal layer and 
disease activity5.
modulation of the intestinal microbiota can be per-
formed either by antibiotics or by probiotics, but the 
former are not good candidates for chronic disease be-
cause of antibiotic resistance, potential side effects, and 
ecological concerns6. Therefore, the use of probiotics in 
iBd could be considered a potential aid to the current 
conventional therapies. an accurate analysis of scientific 
data proves that the efficacy of probiotics in the treat-
ment of various diseases has been amply demonstrated 
and confirmed7-9. actually, several studies have focused 
on the effects of probiotic blends on enteral microbiota, 
especially in those cases of dysbiosis, when the normal 
concentration of “good” bacterial flora is impaired by the 
presence of pathogenic bacteria10,11.
currently, the standard treatment of Uc relies on an 
initial medical management with corticosteroids and anti-
inflammatory agents, such as mesalazine, in conjunction 
with a symptomatic treatment with antidiarrheal agents 
and rehydration. These treatments have been proven not 
to be always reliable in controlling the clinical course of 
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the disease12,13 and present side effects in a significant 
proportion of patients who do not tolerate the existing 
treatments14. in the present open-labeled randomized 
controlled study, standard corticosteroid treatment was 
substituted for a combination therapy (anti-inflammatory 
+ probiotics) for two years, in moderate-to-severe Uc and 
the disease activity was periodically followed-up according 
to the modified mayo disease activity index (mmdai) 
(ref.15).
MATeRIALS AND MeTHODS
From January 2011 to december 2012, 60 Uc pa-
tients were evaluated clinically and endoscopically to 
establish their disease activity, in accordance with the 
mmdai (ref.15), a simplified composite score incorpo-
rating four variables: stool frequency, rectal bleeding, mu-
cosal appearance and physician's rating of disease activity 
(Table 1). By employing a four point scoring scale for 
each variable, the relative simplicity of the index reduces 
the impact of physician and patient subjectivity in dis-
ease scoring. interestingly, the stool frequency score is 
not an absolute number, but relative to “normal” for that 
subject. The mmdai was modified by the deletion of 
“friability” from an endoscopy score equal to 1; in fact, 
the assessment of mucosa “friability” is an important 
subjective parameter and its deletion contributes to the 
objectivity of the chosen score. patients over 18 years of 
age with Uc and a moderate-to-severe disease (activity 
index: 8-12) were considered eligible for the study. The 
diagnosis of Uc, was established on the basis of standard 
clinical, endoscopic and histological criteria. all subjects 
were out-patients, attending our Gastroenterology Unit. 
a condition of steroid dependence, renal impairment, 
pregnancy, lactation or established low compliance, was 
considered as an exclusion criterium. The use of other 
drugs, such as rectal mesalazine or steroid preparations, 
was not allowed during investigation. patients were free to 
leave the study at any time (withdrawal of consent). other 
reasons for withdrawal from the investigation were: lack 
of adherence to the therapeutic schedule or programmed 
controls (< 85%, poor compliance); onset of symptoms of 
relapse, confirmed by instrumental procedures (therapeu-
tic failure); onset of drug-related adverse events requiring 
Table 1. modified mayo disease activity index.
Grade Bowel frequency rectal bleeding physician’s global  
assessment
endoscopy/sigmoidoscopy  
finding
0 Normal number of stools 
per day for this patient
No blood seen Normal Normal or inactive disease
1 1 or 2 more stools than 
normal
streaks of blood with stool 
less than half the time
mild disease mild disease (erythema, decreased  
vascular pattern)
2 3 or 4 more stools than 
normal
obvious blood with stool 
most of the time
moderate disease moderate disease (marked erythema,  
absent vascular pattern, friability,  
erosions)
3 5 or more stools than 
normal
Blood alone passed severe disease severe disease (spontaneous bleeding, 
ulceration)
Table 2. modified mayo disease activity index (mmdai) 
from t0 to t4, in group a, B and a vs B.
mmdai a B a vs B
t0 10.1±1.4 10.2±1.6 ns
t1 7.2±2.0 6.0±1.5 P = 0.0109
t2 5.4±1.3 4.8±0.7 P = 0.0232
t3 5.7±1.4 4.8±0.8 P = 0.0035
t4 6.1±2.0 4.4±0.8 P = 0.0001
Table 3. physician’s global assessment from t0 to t4, in group 
a, B and a vs B.
physician’s global  
assessment
a B a vs B
t0 2.6±0.7 2.7±0.5 ns
t1 1.9±0.7 1.7±0.7 ns
t2 1.5±0.6 1.3±0.5 ns
t3 1.4±0.6 1.2±0.4 ns
t4 1.5±0.6 1.2±0.4 P = 0.0040
interruption of treatment. The study was approved by the 
local ethics committee and all participants subscribed to 
an informed consent.
The patients were divided into two homogeneous 
groups: group a, including 22 male and 8 female subjects 
aged 35-69 years (mean 43 years), was treated pharma-
cologically with 1200 mg of oral mesalazine once-daily 
(mesavancol® 1200 mg cpr, Giuliani spa, milan); group 
B, which included 19 male and 11 female Uc patients 
aged between 28 and 71 years (mean 46 years), was 
treated with a single daily administration of oral mesala-
zine 1200 mg (mesavancol® 1200 mg cpr, Giuliani spa, 
milan) and a double administration of a probiotic blend 
of lactobacillus salivarius, lactobacillus acidophilus 
and Bifidobacterium bifidus strain BGN4 (acronelle®, 
Bromatech srl, milan, italy). The treatment was carried 
out in both groups for two years. 
considering as “t0” the first evaluation, all patients 
were subsequently followed-up for 6 (t1), 12 (t2), 18 (t3) 
and 24 (t4) months. a new reassessment of the activity 
score was carried out at every check-point. data were 
evaluated statistically using the aNoVa method for re-
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep; 160(3):372-377.
374
peated measures (aNoVa repeated measures), and the 
two groups compared by means of t test (unpaired t test).
ReSULTS
during the 24 months of study, patients treated with 
mesalazine and probiotic blend showed better results than 
those reached by patients treated with mesalazine alone. 
in particular, as Table 2 suggests, the benefits of the pro-
biotic blend in combination with the anti-inflammatory 
treatment are tangible and statistically significant after 
a period of at least 18 months. Both groups showed an 
effective improvement of patient general clinical condi-
tion which is reflected by a global improvement of their 
mmdai, but group B patients advantaged from the use 
of probiotics which, probably, enhanced the effects of the 
anti-inflammatory treatment. 
Table 3 underlines the positive effects of single daily 
administration of mesalazine in Uc patients. interestingly, 
in group B, the anti-inflammatory action of the treatment 
is evidently powered by probiotics, which ameliorate the 
clinical response and shorten significantly the time of 
recovery. Furthermore, the combined therapy contributed 
to maintain constantly low the score in group B, whose 
patients showed an acceptable overall clinical condition 
up to the end of the study. However, a slight deterioration 
could be observed over time, in group a. data analysis 
during the 2 years of treatment in both groups, corrobo-
rates the showed results, remarking the slight benefit of 
the combination therapy compared to the sole use of me-
salazine (Table 3).
stool frequency, the second parameter considered, also 
showed a significant improvement due to the combined 
treatment, with a slight reduction of frequency in group 
B compared to group a (Table 4). strangely, there was a 
slight deterioration at 18 months in group B, whereas in 
group a, even in this case, a moderate loss of effectiveness 
of the anti-inflammatory therapy could be recognized over 
time. comparing the two groups, the reduction of stool 
frequency became statistically significant in group B, at 6 
and 24 months of therapy. The table shows a small rever-
sal of the trend at 18 months, when the patients of group 
B seemed to lose the advantage supplied by probiotics. 
considering the endoscopic picture (Table 5), both 
treatments were already effective only after 6 months. in 
group B, patients showed a significant improvement of 
intestinal mucosa aspect, compared to group a, and, as 
already remarked for the overall clinical condition, the 
beneficial effects of combination therapy remained con-
stant for the entire period of study, compared to group a, 
whose patients lost some of those benefits already at t3. 
The evaluation of rectal bleeding more or less followed 
the same time lapse already seen for the endoscopic pic-
ture (Table 6). in fact, bleeding decreased in both groups 
already at t1, but whereas group B enjoyed the positive 
effects of probiotics up to 2 years, showing a certain 
constancy of values at each check-point, group a, once 
again, got progressively worse from 18 months of treat-
ment onwards.
Table 4. stool frequency from t0 to t4, in group a, B  
and a vs B.
stool  
frequency
a B a vs B
t0 2.4±0.5 2.4±0.6 ns
t1 1.8±0.6 1.4±0.5 P = 0.0021
t2 1.3±0.5 1.2±0.4 ns
t3 1.3±0.5 1.3±0.5 ns
t4 1.5±0.6 1.0±0.2 P = 0.0006
Table 5. endoscopic picture from t0 to t4, in group a, B  
and a vs B.
endoscopic 
finding
a B a vs B
t0 2.5±0.5 2.5±0.6 ns
t1 1.8±0.8 1.5±0.6 ns
t2 1.3±0.5 1.2±0.4 ns
t3 1.6±0.5 1.1±0.3 P = 0.0005
t4 1.6±0.6 1.1±0.3 P = 0.0005
Table 6. rectal bleeding from t0 to t4, in group a, B  
and a vs B.
rectal 
bleeding
a B a vs B
t0 2.6±0.6 2.5±0.6 ns
t1 1.7±0.7 1.4±0.5 P = 0.0498
t2 1.3±0.4 1.1±0.3 ns
t3 1.4±0.5 1.1±0.3 P = 0.0374
t4 1.5±0.7 1.1±0.3 P = 0.0024
DISCUSSION
in the last few years, intestinal microbiota seems to be 
increasingly involved in Uc pathogenesis16,17. The charac-
teristic chronic inflammation of the colonic mucosa in 
Uc is likely due to the constant exposure of the mucosal 
layer to antigenic endoluminal stimuli. Numerous studies 
have identified in intestinal dismicrobism the most impor-
tant endoluminal antigenic stimulus; this, along with the 
change of the whole intestinal microenvironment, could 
hyperstimulate the immune system and trigger the inflam-
matory process18-20.
microbiological studies have detected a signifi-
cant reduction of Bifidobacteria and lactobacilli and 
an overgrowth of specific pathogenic strains, such as 
deltaproteobacteria and Bilophila wadsworthia. The use 
of probiotics in combination with the standard treatment, 
improves patients’ quality of life and life expectancy, re-
ducing significantly clinical symptoms and minimizing 
side effects21-25. The results of our study confirm the 
beneficial effects of probiotics on Uc activity, partly by 
improving patient’s response to anti-inflammatory treat-
ment. comparing patients treated with probiotic blend 
and mesalazine, and those patients who received the anti-
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inflammatory alone, data report a significant improve-
ment of mmdai in the former group, after 18 months. 
interestingly, the association of probiotics with mesala-
zine, seems to guarantee a stable effect in the whole pe-
riod of observation, different from the anti-inflammatory 
therapy alone, which seems to be burdened by an unsteady 
response. oral 5-asa administered once daily has been 
demonstrated to be as effective and safe as conventional 
dosing (twice or three times daily) for maintenance of 
remission in quiescent Uc (ref.26). The choice of testing 
a specific probiotic blend (acronelle®, Bromatech srl, 
milan, italy)  was suggested by the distinguishing features 
of the bacterial strains contained in the considered probi-
otic blend: lactobacillus salivarius has a high anti-inflam-
matory and antibacterial activity, especially against some 
of those pathogenic bacterial strains, usually present on 
the intestinal mucosa of iBd patients27; Bifidobacterium 
bifidum BGN 4 supports lactobacilli against inflam-
mation, thanks to the chiro-inositol present in its cell 
membrane, which seems to reduce the production of 
pro-inflammatory cytokines28. although guidelines29 sug-
gest to treat moderate-to-severe Uc with corticosteroids, 
the contemporary use of mesavancol® and acronelle® 
allowed to reach an encouraging result, avoiding all those 
therapy side effects which usually decrease patient compli-
ance. For the first time, the long-term efficacy (2 years) of 
such a probiotic blend has been proven, also demonstrat-
ing the synergistic effect on disease activity, especially 
when coupled with anti-inflammatory treatment. several 
authors have already contributed to research in this field, 
however, none of them has followed-up moderate-to-severe 
Uc patients, for a such long period of time. ishikawa et 
al. (ref.30) reported that Bifidobacteria-fermented milk 
(BFm) supplementation reduces the luminal butyrate 
concentration, a key molecule in the remission of colitis. 
This reduction reflects the increased uptake or oxidation 
of scFas by the improved colorectal mucosa. similarly, 
Kato et al. (ref.31) found increased levels of faecal butyr-
ate, propionate, and scFa acid concentrations in patients 
with active Uc (mild to moderate), who received BFm 
together with conventional treatment. in this pilot study, 
patients supplemented with BFm showed a significant-
ly lower clinical activity index than the placebo group. 
likewise, the post-treatment endoscopic index and histo-
logical score were reduced in the BFm group. probio-Tec 
aB-25, a mixture of lactobacillus acidophilus strain la-5 
and Bifidobacterium animalis subsp. lactis strain Bb-12, 
was tested for the maintenance of remission in patients 
with left-sided Uc, in a 1-year, prospective, randomized, 
double-blind and placebo controlled trial32. The safety and 
tolerance of probio-Tec aB-25 and the placebo were good. 
Gastrointestinal symptoms were reported equally in both 
treatment groups and a relationship between probio-Tec 
25 and gastrointestinal side effects could not be estab-
lished. at weeks 4 and 28, Bb-12 or la-5 were detected in 
11 patients receiving probiotics. Five patients in the pro-
biotic group (25%) and one patient in the placebo group 
(8%) maintained remission after 1 year of treatment. in 
the probiotic group, the median time to relapse was 125.5 
days, versus 104 days in the placebo group. The use of 
BiFico (oral capsules of live enterococci, bifidobacteria, 
and lactobacilli) in combination with sulphasalazine and 
glucocorticoid exerts some beneficial effects in preventing 
the relapse of Uc (ref.33). The administration of BiFico 
plus sulphasalazine and glucocorticoid to Uc patients 
enlarged the number of bifidobacteria and lactobacilli 
and reduced the number of enterococci, bacteroides, 
and bifidobacteria present in the faeces compared with 
the control group. The most studied probiotic in clinical 
trials is lactobacillus rhamnosus, which is present in the 
bowel of healthy individuals. Zocco et al. (ref.34) studied 
the efficacy of lactobacillus rhamnosus GG (lGG) 
supplementation versus standard mesalazine for main-
taining disease remission in Uc patients. after 6 and 12 
months of treatment, the percentage of patients maintain-
ing clinical remission was, respectively, 91% and 85% for 
the lGG group (1.8 × 1010 viable bacteria/day), 87% and 
80% for the mesalazine group (2400 mg/day), and 94% 
and 84% for the combined treatment (lGG plus mesala-
zine). The oral administration of lacteol (lacteol Fort, 
rameda, egypt), a probiotic preparation that contains 1 × 
1010 cFU of lactobacillus delbrueckii and lactobacillus 
fermentum, together with 2400 mg/day of sulfasalazine, 
during 8 weeks, to Uc patients with chronic diarrhea, 
inhibited the extent of inflammation, prevented muco-
sal injury, and alleviated colitis35. in children with distal 
active Uc, rectal administration of lactobacillus reuteri 
aTcc 55730 (as an enema solution containing 1 × 1010 
cFU) for 8 weeks in addition to standard oral mesalazine, 
resulted in a significant decrease in the mdai compared 
with the children that received the corresponding placebo. 
in addition, all of the children on lactobacillus reuteri 
had a clinical response, whereas only 53% of the chil-
dren on the placebo responded. clinical remission was 
achieved in 31% of the lactobacillus reuteri group and in 
no children of the placebo group36. d’incà et al. (ref.37) 
evaluated the effect of an 8-week oral and/or rectal admin-
istration of lactobacillus casei dG on colonic-associated 
microbiota, mucosal cytokine balance, and Tlr expres-
sion in patients with mild left-sided Uc. The patients were 
divided into three groups: the first group received oral 
5-asa alone, the second group received oral 5-asa plus 
oral lactobacillus casei dG (8 × 108 cFU), and the third 
group received oral 5-asa and rectal lactobacillus casei 
dG (8 × 108 cFU). a significant improvement of the 
histological scores was found in patients receiving the pro-
biotic strain by the oral or rectal route of administration. 
Nevertheless, oral supplementation with lactobacillus 
casei dG did not have a significant effect on the counts of 
enterobacteriaceae or lactobacillus. However, the occur-
rence of lactobacillus and enterobacteriaceae cultured 
from biopsy specimens was increased and decreased, re-
spectively, in the group that took the probiotic rectally. 
moreover, the rectal administration of lactobacillus casei 
dG significantly reduced Tlr-4 and il-1β levels and sig-
nificantly increased mucosal il-10.
probiotics act into the inflamed intestine, destroying 
“bad” bacterial flora and restoring previous micro-envi-
ronment conditions. probably, such an effect this prevents 
that abnormal reaction of the human immune system at 
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the base of intestinal autoimmune diseases. in this case, 
patients treated with probiotics showed an overall im-
provement of all studied parameters: patients showed a 
better clinical response, reduced significantly their stool 
frequency, maintained easily their haemoglobin values 
and exhibited a significant improvement of their gut 
mucosa condition. likely, a random choice of probiotic 
strains should not be the right way to cure iBd definitely, 
but the present study demonstrates the efficacy of some 
“good” bacterial strains in assisting anti-inflammatory 
drug mechanism of action. 
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